Korean CDMOs Secure Major Global Contracts: Samsung Biologics, Celltrion, and Lotte Biologics Reshape Outsourced Manufacturing

June 9, 2026 — South Korean CDMOs are rapidly expanding their global footprint, winning major contracts across Europe, the U.S., the U.K., and Japan. Announcements from Samsung Biologics, SK bioscience, Lotte Biologics, Prestige Biologics, and Celltrion signal a new phase of growth that creates significant opportunities for API and raw material suppliers.

The Contract Wins

• Samsung Biologics: Signed a $188.95 million contract with a European pharmaceutical company for biologics contract manufacturing, running through March 2032.
• Celltrion: Secured a $473 million biologics CMO agreement with Eli Lilly in January, followed by another $191 million contract (expandable to $243 million) with a global pharmaceutical company in March. CMO order backlog surpassed $650 million in Q1 2026.
• Lotte Biologics: Signed an additional manufacturing agreement with Ottimo Pharma for drug substance production of antibody candidate Jankistomig at its Syracuse, NY facility, expanding into process development.
• SK bioscience: Through subsidiary IDT Biologika, signed a contract with MSD for drug product development and manufacturing of a second-generation Ebola vaccine.
• Prestige Biologics: Secured its first CDMO contract with a Japanese global pharmaceutical company, marking entry into the Japanese market.

What's Driving Korean CDMO Growth

• Manufacturing scale: Heavy investment in large-scale biologics capacity, with Samsung Biologics operating one of the world's largest CDMO facilities
• Quality track record: Years of FDA and EMA inspection successes have built credibility with global pharmaceutical companies
• Cost competitiveness: Competitive pricing relative to Western CDMOs while maintaining rigorous quality standards
• Geographic diversification: Dual-site manufacturing systems connecting North America and Asia reduce supply chain risk
• Strategic acquisitions: Celltrion's New Jersey facility purchase demonstrates how Korean CDMOs are acquiring Western capabilities

Implications for API and Raw Material Suppliers

As Korean CDMOs scale to fulfill growing order books, demand for supporting inputs increases proportionally:

• Cell culture media: Serum-free, animal-component-free media for CHO cell culture in expanding biologics facilities
• Chromatography resins: Protein A resins, ion exchange media, and HIC materials consumed during manufacturing scale-up
• Single-use technologies: Bioreactor bags, tubing, connectors, and filtration assemblies for modern biologics platforms
• Viral safety reagents: Viral inactivation and filtration materials for product safety
• Formulation excipients: GMP-grade stabilizers, surfactants, and buffers for drug product manufacturing
• Analytical services: Comparability studies, stability programs, and release testing for growing product pipelines

Competitive Dynamics

The rise of Korean CDMOs is reshaping the global pharmaceutical outsourcing landscape. Western CDMOs face increasing competition from Korean manufacturers offering comparable quality at competitive prices. For API and raw material suppliers, this creates both opportunities — Korean CDMOs seeking new supplier relationships — and risks as competitive pressure drives cost optimization across the industry. Suppliers serving both Korean and Western CDMOs with consistent quality and competitive pricing will be best positioned.

Strategic Recommendations

• Engage early in the expansion cycle: Korean CDMOs are actively building capacity — suppliers establishing relationships now are best positioned for long-term agreements
• Offer integrated solutions: As CDMOs expand into process development and analytical services, bundled raw material plus technical support offerings differentiate suppliers
• Prepare for global delivery: Korean CDMOs operate across multiple geographies, requiring consistent quality and reliable delivery worldwide
• Monitor the Celltrion effect: Celltrion's expansion from biosimilar manufacturer to full-service CDMO represents a model others may follow

Outlook

The Korean CDMO expansion reflects years of strategic investment in manufacturing capabilities, quality systems, and global market development. As these manufacturers continue to win contracts from major pharmaceutical companies, their influence on the global supply chain will only grow. For API and raw material suppliers, the Korean CDMO market is no longer a niche opportunity — it is a major growth segment demanding strategic attention.